OraSure Technologies (OSUR) Stock Price
OraSure Technologies Price
Revenue has compounded at 2.8% per year over the past 19 years to 115.02 M USD. Earnings per share have grown at 11.4% per year over the last 17 years. OraSure Technologies's net margin stands at -59.8%, down from -9.8% several years earlier. Analysts set a median price target of 4.00 USD, implying 0.4% above the current price. Of 6 analysts, 0 rate the stock a buy — an overall Sell consensus.
OraSure Technologies stock price
OraSure Technologies business model & stock analysis
Frequently asked questions about OraSure Technologies
OraSure Technologies Inc. operates under a diversified business model. The company specializes in the development, manufacturing, and distribution of point-of-care diagnostic and specimen collection devices. OraSure's products serve various industries, including healthcare, criminal justice, drug treatment, and public health. With a focus on innovative technologies, OraSure delivers solutions for rapid diagnostic testing, such as HIV and hepatitis C detection. The company also offers oral fluid collection devices for DNA testing and substance abuse monitoring. Through its comprehensive business model, OraSure Technologies Inc. remains committed to enhancing healthcare outcomes and improving overall testing processes.
OraSure Technologies Inc is primarily active in the biotechnology and healthcare industries.
The main competitors of OraSure Technologies Inc in the market are Abbott Laboratories, Quidel Corporation, and Hologic, Inc.
OraSure Technologies Inc. is a leading global provider of diagnostic testing and specimen collection devices. Founded in 1987, the company has a rich history of developing innovative solutions for infectious diseases and substance abuse testing. OraSure Technologies Inc. is focused on improving public health by offering non-invasive testing options that are accurate, reliable, and user-friendly. With a diverse portfolio of products, including the OraQuick® In-Home HIV Test and the OraCollect™ DNA Device, the company aims to empower individuals and healthcare professionals with effective tools for early detection and prevention. OraSure Technologies Inc. continues to drive advancements in diagnostics, making a significant impact on the healthcare industry.
OraSure Technologies Inc has achieved several significant milestones. One of the notable achievements is the development and FDA approval of the OraQuick® In-Home HIV Test, which is the first rapid HIV test that can be used by individuals in the comfort of their own homes. This groundbreaking product has helped to increase HIV testing rates and improve early detection. Additionally, OraSure Technologies Inc has made significant strides in the field of oral fluid diagnostics, paving the way for advancements in drug testing and healthcare diagnostics. The company continues to innovate and collaborate with industry partners, solidifying its position as a leader in the diagnostic testing space.
OraSure Technologies Inc is primarily present in the United States.
OraSure Technologies Inc represents core values of innovation, integrity, and excellence. With a strong corporate philosophy, the company strives to make a positive impact on healthcare by developing and providing innovative diagnostic tests and specimen collection devices. OraSure Technologies Inc is dedicated to improving public health outcomes through its commitment to quality, accuracy, and reliability. Through cutting-edge technologies and a focus on customer satisfaction, the company has become a leader in the industry, delivering accurate and rapid diagnostic solutions. OraSure Technologies Inc's dedication to constant innovation and maintaining the highest standards makes it a trusted name in the healthcare sector.
Analysts currently set an average price target of 4.00 USD for the OraSure Technologies stock (median: 4.00 USD), implying +0.4 % versus the latest price. The consensus is based on 6 analyst ratings.
6 analysts currently rate the OraSure Technologies stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect OraSure Technologies to generate revenue of 122.11 M USD and earnings per share of -0.66 USD.
Converted at the current exchange rate, the OraSure Technologies share trades at 3.56 EUR (3.98 USD).
The OraSure Technologies share (OSUR) is listed on 4 stock exchanges, including: NASDAQ (OSUR), SIX (Zürich) (EP3.SW), Frankfurt (EP3.F), München (EP3.MU).
OraSure Technologies Inc is a US company specializing in the development and marketing of diagnostic tests, devices, and medical accessories. It was founded in 2000 as a spin-off of Epitope Inc. Currently, OraSure Technologies Inc employs over 500 employees and is headquartered in Bethlehem, Pennsylvania. The company's business model is based on various divisions focusing on different medical applications. These include divisions such as "Infectious Diseases," "Clinical Laboratory Diagnostics," and "Molecular Diagnostics." In the Infectious Diseases division, OraSure Technologies Inc offers various tests for detecting infections, including the OraQuick® HCV Rapid Antibody Test, a test for the rapid and easy detection of Hepatitis C antibodies in the blood. The company also manufactures the OraQuick® HIV Self-Test and the OraQuick® In-Home HIV Test, which provide a simple and convenient way for patients to test themselves for HIV. The Clinical Laboratory Diagnostics division focuses on the development of diagnostic tests for use in clinical laboratories. OraSure Technologies Inc offers products such as the Intercept® i2F Body Fluid Collection Device and the Intercept® Oral Fluid Drug Test, which enable fast and reliable analysis of various body fluids. The Molecular Diagnostics division focuses on the development of molecular biological tests for detecting diseases based on DNA and RNA analysis. The company offers products such as the OraSure® OMNIgene® GUT Kit for stabilizing DNA samples and the OraQuick® Ebola Rapid Antigen Test, which allows for rapid and reliable detection of Ebola antigens. In addition to the development and marketing of diagnostic tests and devices, OraSure Technologies Inc also offers medical diagnostic accessories. These include the Intercept® Collection Kit and the OraSure® Sample Collection Device, which enable reliable and secure sample collection for blood tests and other examinations. OraSure Technologies Inc's business model is based on a strong focus on research and development of new products, as well as the safe and reliable production of diagnostic tests and devices for use in medical facilities. Through close collaboration with leading medical research institutes and universities, OraSure Technologies Inc is able to develop innovative and groundbreaking products for medical diagnostics, making an important contribution to healthcare and disease prevention.
The expected revenue of OraSure Technologies is 122.11 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of OraSure Technologies is -47.34 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of OraSure Technologies is currently -6.02. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the OraSure Technologies stock.
The price-to-sales ratio (P/S) of OraSure Technologies is currently 2.34. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the OraSure Technologies stock.
The Eulerpool Quality Score for OraSure Technologies is 1/10.
The ISIN of OraSure Technologies is US68554V1089. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of OraSure Technologies is 881351. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of OraSure Technologies is OSUR. The ticker symbol is used to trade OraSure Technologies shares on the stock exchange.
OraSure Technologies stock
OraSure Technologies Peer Group
OraSure Technologies Ticker
OraSure Technologies FIGI
All fundamentals and in-depth analysis of OraSure Technologies
Our stock analysis for OraSure Technologies stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OraSure Technologies. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.